Lipe & Dalton Vertex Pharmaceuticals Inc Transaction History
Lipe & Dalton
- $179 Million
- Q1 2025
A detailed history of Lipe & Dalton transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Lipe & Dalton holds 4,581 shares of VRTX stock, worth $2.02 Million. This represents 1.24% of its overall portfolio holdings.
Number of Shares
4,581
Previous 4,981
8.03%
Holding current value
$2.02 Million
Previous $2.01 Million
10.72%
% of portfolio
1.24%
Previous 1.06%
Shares
15 transactions
Others Institutions Holding VRTX
# of Institutions
1,833Shares Held
233MCall Options Held
1.38MPut Options Held
1.08M-
Capital World Investors Los Angeles, CA28.5MShares$12.6 Billion2.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.5MShares$10.4 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.4 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA14.5MShares$6.41 Billion1.6% of portfolio
-
State Street Corp Boston, MA11.8MShares$5.2 Billion0.24% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $113B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...